A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression by unknown
PRECLINICAL STUDY
A prospective study to assess the clinical utility of serum HER2
extracellular domain in breast cancer with HER2 overexpression
Nathalie Reix1,2 • Charlotte Malina3 • Marie-Pierre Chenard4 • Jean-Pierre Bellocq4 •
Ste´phanie Delpous5 • Se´bastien Molie`re6 • Anthony Sevrin7 • Karl Neuberger7 •
Catherine Tomasetto5 • Carole Mathelin3,5
Received: 15 June 2016 / Accepted: 23 September 2016 / Published online: 5 October 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Purpose We explored the clinical utility of human epi-
dermal growth factor receptor-2 extracellular domain
(HER2/ECD) in patients treated for an invasive breast
cancer with HER2 overexpression.
Methods We prospectively studied HER2/ECD levels in
the sera of 334 women included between 2007 and 2014,
all treated with trastuzumab. HER2/ECD levels were
measured at diagnosis, during treatments, and along the
follow-up. We investigated the relationship of HER2/ECD
with other clinicopathological parameters at diagnosis, its
prognosis value, and its utility during the monitoring of a
neoadjuvant treatment and the follow-up.
Results Elevated HER2/ECD at diagnosis correlated posi-
tively with parameters associated with tumor aggressiveness.
Disease-free survival of non-metastatic patients was signifi-
cantly shorter in patients with high HER2/ECD at diagnosis
(HR = 13.6, 95 % CI 1.6–113.6, P\ 0.0001). Progression-
free survival ofmetastatic patients was better for patients with
lowHER2/ECD (HR = 2.6, 95 %CI 1.2–5.3,P = 0.033). A
multivariate analysis revealed that HER2/ECD level at diag-
nosis was an independent prognosis factor. During neoadju-
vant therapy, a significant decrease in HER2/ECD was
reported only for the complete histological response group
(P = 0.031). During the follow-up, HER2/ECD helped pre-
dict relapse, disease progression, and metastases before
imaging in 18.6 % cases of the studied cohort.
Conclusions HER2/ECD is a prognosis factor that is
valuable in evaluating the neoadjuvant treatment effi-
ciency. HER2/ECD also appears to be a helpful surveil-
lance biomarker for the early diagnosis of relapses and to
predict the fate of metastases. This study brings evidences
to support the use of HER2/ECD in the management of
HER2-positive breast cancer.
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Introduction
About 15–20 % breast carcinomas have an overexpression
of human epidermal growth factor receptor-2 (HER2) [1].
This overexpression has been associated with a more
aggressive disease, a poor clinical prognosis and the ther-
apeutic success of trastuzumab [2]. HER2 has an extra-
cellular domain (ECD) mainly produced by HER2 cleav-
age and released into circulation [3]. Several observations
suggest that this cleavage is of clinical importance [4].
Indeed, the truncated form is 10 to 100-fold more
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oncogenic than the full-length HER2 form [5]. A wide
range of studies over the last 20 years reports that high
HER2/ECD levels detected in the serum are associated
with tumor aggressiveness, a less positive prognosis, and
disease progression [6, 7]. Consequently, elevated HER2/
ECD levels may represent a subgroup of HER2-positive
tumors with a higher level of HER2 cleavage that is
associated to a more aggressive clinical course. Therefore,
HER2/ECD could be a biomarker that helps identify this
subgroup of tumor and improve the risk stratification.
However, the results on the clinical importance of
HER2/ECD are based on studies that have not all been
conducted according to the international recommendations
for tumor markers [8] and that did not respect every
specific recommendation existing for HER2/ECD quan-
tification. Indeed, according to the Food and Drug
Administration, HER2/ECD must be quantified with one of
the two validated immunoenzymatic methods; the ELISA
manual method and the automatic method Immuno-1, both
developed by Siemens Healthcare Diagnostics. These
assays use the same set of two monoclonal antibodies, the
same calibration material and a unique pathological
threshold C15 ng/mL [9, 10]. Furthermore, pathologies
that are associated with an elevation of HER2/ECD in
40–60 % of patients [11] must be excluded, specifically
hepatic ones. A review of the literature shows that there are
few prospective studies meeting these criteria [12] and that
more studies are needed to consolidate the utility of this
assay in the management of breast cancer.
On the basis of these findings, we conducted a
prospective study in accordance with the international
guidelines and used an FDA-approved assay. In this study,
we analyzed HER2/ECD circulating levels in a series of
patients treated for an invasive breast cancer with HER2
overexpression, and examined their association with
pathological parameters, prognosis, therapeutic response,
and disease progression.
Patients and methods
The study was conducted in accordance with the REMARK
criteria [8].
Study design
This clinical study was prospective. The cohort consisted
of 334 consecutive Caucasian women having a positive
HER2 breast cancer treated with trastuzumab. Patients
were enrolled from January 2007 to April 2014 at a single
French regional hospital: the Hoˆpitaux Universitaires de
Strasbourg. All patients gave their written informed con-
sent. The French ethic committee gave its agreement for
the conduction of this study. Exclusion criteria were neg-
ative HER2 tumor and hepatic diseases. The study design is
presented in Fig. 1 and explained below.
Clinical and anatomopathological parameters
Clinical parameters obtained for all patients included lymph
node status, metastatic status, age and menopausal status at
diagnosis. The primary tumor characteristics included size
and histological type. Histological grade was evaluated using
the Elston–Ellismodification of the SBR grading system [13].
Lymph node involvement was analyzed using haematoxylin-
eosin (HE) and immunohistochemistry (IHC) (anti-cytoker-
atin) in cases where the sentinel lymph node procedure was
used. Estrogen receptors (ER) and progesterone receptors
(PR) were examined using IHC with the monoclonal anti-
bodies SP1 for ER (Ventana Confirm anti-ER SP1) and 1E2
(Ventana Confirm anti-ER SP1anti-PR 1E2) for PR. These
were quantified using the international H-score value [14].
Vascular invasion (VI) was defined as the presence of cancer
cell microemboli in lymphatic and/or blood vessels histolog-
ically estimated around primary tumors [15].
Tissue HER2 status determination
Tissue HER2 status was analyzed by immunohistochem-
istry (IHC) (clone Ventana pathway HER2 4B5) in all
tumors and by in situ hybridization (ISH) for score
2? tumors by IHC (INFORM HER2 dual ISH DNA probe
cocktail, Ventana) according to the ASCO and to experts
recommendations [1, 16, 17]. The laboratory regularly
contributes to the National Breast Pathology External
Quality Assessment scheme.
HER2/ECD and CA 15.3 analyses
From January 2007 to October 2008, serum samples were
analyzed for HER2/ECD using a manual ELISA assay kit
(Siemens Healthcare Diagnostics). The assay has a limit of
quantification (LOQ) of 1.5 ng/mL, a linear measuring
range up to 35 ng/mL, and day-to-day variability at 4.1,
10.2, and 20.8 ng/mL of 9.1, 8.6, and 6.7 %, respectively.
It was replaced starting on 7 October 2008 by an automated
sandwich immunoassay using direct chemiluminescent
technology (ADVIA Centaur HER2/neu assay, Siemens
Healthcare Diagnostics) with LOQ of 0.5 ng/mL, a linear
measuring range up to 350 ng/mL and an interassay CV of
5.7 % at 13.9 ng/mL and 4.3 % at 97.6 ng/mL. Serum
HER2/ECD was considered positive when C15 ng/mL for
both the assays. A strong correlation between the results of
automated and the manual assays was described [18].
Measurements of carbohydrate antigen 15.3 (CA 15.3)
were performed using an automated immunoassay on
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Kryptor (Brahms, Thermo scientific). CA 15.3 serum val-
ues above 30 U/mL were considered abnormal.
HER2/ECD and CA 15.3 during the monitoring
of metastatic breast cancer
During the follow-up of the 48 patients of the metastatic
group, we studied the correlation between HER2/ECD and
CA 15.3 level changes and the evolution of target lesions
(bone, liver, lung, brain metastases) on CT, PET, or
scintigraphy. Change in HER2/ECD level was evaluated
during a three-month period before imaging. Each imaging
evaluation with associated HER2/ECD was considered. In
consequence, if one patient had undergone several imaging
examinations with associated HER2/ECD measurements
during the follow-up, then each biological-imaging corre-
lation was analyzed independently.
We considered that HER2/ECD level was consistent
with metastasis progression when the increase between the
result obtained 3 months before imaging and the result
obtained just before imaging was at least 10 % or when the
level remained elevated. Conversely, we considered that
HER2/ECD was correlated with metastasis regression
when the decrease was at least -10 % or when the level
remained negative. The same analysis was applied to CA
15.3. These values (±10 %) were based on the day-to-day
variability results as described in the previous paragraph.
Statistical analyses
To assess the association among clinicopathological vari-
ables and the levels of HER2/ECD, P values were calcu-
lated using the v2 test.
ANOVA I with a Student–Newman–Keuls post hoc test
was used after logarithm transformation of data to evaluate
HER2/ECD level differences between groups.
Univariate investigations of the relationship between
baseline HER2/ECD levels and overall survival (OS),
disease-free survival (DFS) for non-metastatic patients and
progression-free survival (PFS) for metastatic patients were
conducted using the Kaplan–Meier method. The log-rank
test was used to test the differences between survival
curves. Hazard ratios (HR) with confidence intervals (95 %
CI) were computed through a multivariate analysis using
Cox proportional hazards regressions, adjusting for the
following variables: grade, nodal status, vascular invasion,
estrogen and progesterone receptors, HER2 status, and CA
15.3.
HER2/ECD level evolution during neoadjuvant therapy
and during the monitoring of therapy in the metastatic
group was analyzed using the Wilcoxon test for paired
samples.
For all tests, a P value\ 0.05 was considered as sig-
nificant. Statistical analyses were performed with the
MedCalc software version 12.2 (Mariakerke, Belgium),
and the R software version 2.7 for computing the Cox
regression.
Results
Clinical and biological characteristics of breast
cancer subsets
Patients and tumor characteristics at the diagnosis are
detailed in Table 1. These data show that some of the
Fig. 1 Design of the study. All enrolled patients had an invasive breast cancer (IBC) with HER2 overexpression. They were divided into three
groups: Group adjuvant (A), Group neoadjuvant (NA) and Group metastases (M)
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cohort characteristics such as the mean age at diagnosis,
the percentage of node positive patients, the grade and
tumor type distributions, and the rate of positive hormone
receptors are consistent with the European breast cancer
population characteristics [19, 20].
Patients were divided into three groups according to the
pathological characteristics of breast cancer at diagnosis:
(1) patients devoid of distant metastasis first treated with
surgery (group Adjuvant (A)), (2) patients devoid of distant
metastasis first treated with systemic therapy by trastuzu-
mab and chemotherapy or hormone therapy (group Neo-
adjuvant (NA)), (3) patients with distant metastases (group
Metastases (M)) (Fig. 1). Among the 48 metastatic
patients, 35 cases involved one organ (13 cases of bone
metastasis, 9 cases of liver metastasis, 2 cases of brain
metastasis, 9 cases of lung metastasis, 2 cases of skin
metastasis).
Elevated HER2/ECD levels at diagnosis were
associated with advanced breast cancer
HER2/ECD at diagnosis was examined in order to high-
light differences in HER2/ECD levels between patient
groups (A, NA or M). The results are the following: in
group A, 6.7 % of values were higher than 15 ng/mL,
15.1 % in group NA, and 47.9 % in group M (Table 1). We
noticed a significant difference in HER2/ECD levels
between the three groups: a higher HER2/ECD level was
observed for the group M (P\ 0.001). Thus, we can
conclude that patients with distant metastases presented
more elevated HER2/ECD levels at the time of diagnosis
compared to non-metastatic patients.
Among relationships with histological parameters
at diagnosis, HER2/ECD was not correlated
with HER2 overexpression intensity (HER2 21 vs
HER2 31)
We observed relationships between HER2/ECD levels at
diagnosis alongside the most discriminating prognosis
factors in term of patient care. Statistical associations of
HER2/ECD with histological and biological parameters are
presented in Table 2. The v2 P indicated a correlation
between high HER2/ECD levels at diagnosis and vascular
invasion, metastases, negativity of estrogen receptors, and
CA 15.3 level C30 U/mL (Table 2). We observed no sig-
nificant correlation between high HER2/ECD levels and
menopausal status, lymph node status, grade, or proges-
terone receptor status. We also noticed a lack of correlation
between HER2/ECD levels at diagnosis and HER2 over-
expression intensity. This can be explained by the fact that
tumors scored 3? can be quite heterogeneous with cancer
cells expressing high and low level of HER2 that can co-
exist in the same tumor, or with cancer cells diluted in a
rich tumor stroma. Thus, HER2/ECD is not a substitute of
tumor HER2 status determination.
HER2/ECD level at diagnosis was an independent
prognosis factor for overall survival
Testing whether HER2/ECD is a prognosis factor or not
was done by analyzing the patients survival. The median
duration of the follow-up was 68 months for the entire
cohort (mean 61 months, range 6–88 months). Among the
163 non-metastatic patients followed at least 5 years after
the diagnosis, 97.5 % are still alive. In the 32 patients of
the metastatic group followed at least 5 years, the overall
survival is 62.5 %. The relationship between HER2/ECD
levels at diagnosis and survival is shown in Fig. 2. DFS of
non-metastatic patients was significantly shorter in patients
with high HER2/ECD levels (C15 ng/mL) compared to
patients with low HER2/ECD levels (\15 ng/mL) (HR
= 13.6, 95 % CI 1.6–113.6, P\ 0.0001) (Fig. 2A). PFS of
metastatic patients was better for patients with a low
HER2/ECD level (HR = 2.6, 95 % CI 1.2–5.3, P = 0.033)
(Fig. 2B). OS was significantly shorter for patients with
high HER2/ECD levels (HR = 8.90, 95 % CI 2.8–28.7,
P\ 0.0001) (Fig. 2C). Multivariate analyses revealed that
HER2/ECD was an independent prognosis factor for OS.
Indeed, high serum HER2/ECD levels were strongly
associated with worse overall survival (HR = 4.88, 95 %
CI 1.6–14.9, P = 0.010). In conclusion, high HER2/ECD
levels were associated with the overall survival duration for
the HER2 overexpressing breast tumors of this study.
A significant decrease of HER2/ECD level
during trastuzumab neaoadjuvant therapy
was an indicator of the treatment efficacy
We followed the evolution of HER2/ECD levels during the
neoadjuvant treatment of group NA in order to test whether
the changes of this biomarker were correlated with the
efficacy of the neoadjuvant therapy. The median duration
of a neoadjuvant therapy was 4.3 months (SD 2.0). In the
complete histological response group, the results showed
no significant evolution of HER2/ECD levels during the
NA chemotherapy administered alone (P = 0.094). These
same results revealed a significant decrease of HER2/ECD
levels during the period ranging from the moment trastu-
zumab was added to NA chemotherapy to the end of the
NA treatments (P = 0.031, Fig. 3A). In the incomplete
histological response group, we found no significant dif-
ference in HER2/ECD levels during the neoadjuvant
treatment. In each group, we found no difference in CA
15.3 levels (Fig. 3B). These data were obtained from a
small effective of patients (\20 in the incomplete and
252 Breast Cancer Res Treat (2016) 160:249–259
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complete response groups). Indeed, the study was designed
to test HER2/ECD before and after NA therapy. Conse-
quently, HER2/ECD was not systematically quantified
before trastuzumab introduction. Thereby, the question
about the utility of HER2/ECD as a useful circulating
biomarker to follow the trastuzumab therapy efficacy
Table 1 Characteristics at diagnosis of the 334 patients and 336 breast cancer tumors included in the series
Adjuvant group Neo-adjuvant group Metastatic group Total
Number 180 106 48 334
Age (years)
Average (range) 55 (27–98) 53 (24–84) 58 (23–91) 55 (23–98)











C55 years 83 45 26 154 (46.1 %)
Breast tumor size (mm)
Average (range) 19.5 (1–60) 42.5 (8–100) 36.8 (11–80) 29.1 (1–100)
Median (SD) 17 (11) 40 (21.4) 30 (22.1) 25 (19.6)
ND 0 2 3 5
Number of patients with positive node 76 33 25 134 (40.1 %)
Average (range) 1.03 (1–3) 1.33 (1–2) 1.6 (1–3) 1.21 (13)
Median (SD) 1 (0.23) 1 (0.48) 1 (0.71) 1 (0.48)
Grade
Low grade 12 3 1 16 (4.8 %)
Intermediate grade 60 46 16 122 (36.5 %)
High grade 107 55 26 188 (56.3 %)
ND 1 2 5 8
Tumor type
Ductal 171 101 30 302 (89.9 %)
Lobular 6 4 9 19 (5.7 %)
Ductal and lobular 2 1 0 3 (0.9 %)
Tubular 2 0 0 2 (0.6 %)
Micropapillary 0 0 1 1 (0.3 %)
Medullar 0 0 2 2 (0.6 %)
ND 0 0 7 7 (2.0 %)
Predictive factors
HR? 123 64 29 216 (64.7 %)
HR- 57 42 19 118 (35.3 %)
ND 1 0 1 2
HER2 3? 156 101 47 304 (91 %)
HER2 2 ? ISH? 24 5 1 30 (9 %)
HER2/ECD (ng/mL)
\15 168 90 25 283 (84.7 %)
C15 12 16 23 51 (15.3 %)
Average (range) 9.6 (2.4–25.6) 11.5 (5–53.9) 42.3 (6.4–714) 14.9 (2.4–714)
Median (SD) 8.8 (3.1) 9.2 (7.7) 14.7 (105.2) 9.3 (41.4)
CA 15.3 (U/mL)
\30 167 84 27 278 (83.2 %)
C30 13 22 21 56 (16.8 %)
Average (range) 18.6 (6.3–77.6) 24.6 (5–107.4) 177.2 (9.3–2542) 43 (5–2542)
Median (SD) 16.6 (8.9) 20.7 (14.2) 26.0 (423.3) 19 (168.6)
ND not done, HR hormone receptors
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during the neoadjuvant treatment of invasive breast cancer
with HER2 overexpression, while CA 15.3 cannot, remains
to be addressed in future studies.
HER2/ECD was useful to detect certain cancer
recurrences at an early stage
We focused on the usefulness of HER2/ECD for an early
detection of recurrence. During the follow-up, we observed
70 events (progression, metastases, and death) in the cohort
of 334 patients. An increase of HER2/ECD without any
change in CA 15.3 levels helped to predict relapse, disease
progression, and metastasis before imaging in 18.6 %
cases. In 35.7 % of cases, we noticed a concomitant
increase of HER2/ECD levels and CA 15.3 before the
diagnosis of relapses or metastases. In 8.6 % of cases, CA
15.3 increased before the diagnosis of cancer recurrence
without any change in HER2/ECD levels. However, for
37.1 % of patients, neither HER2/ECD nor CA 15.3 helped
to predict the occurrence of metastases. To conclude,
HER2/ECD provides in some situations an additional
information over tumor marker CA 15.3 for the detection
of early cancer recurrence.
HER2/ECD was useful to predict the fate
of metastases
During the follow-up of the 48 patients of the metastatic
group, we assessed if changes inHER2/ECD levels (increase
or decrease) 3 months before imaging were consistent with
imaging results (metastasis progression or regression).
Sixty-five imaging results were obtained. Figure 4A and B
show that during metastasis progression (Fig. 4A) or
regression (Fig. 4B), HER2/ECDwas significantly modified
(levels increased or decreased, respectively) considering all
events.We observed the same significant results for CA 15.3
evolution (Fig. 4C,D).When focusing on specificmetastasis
localizations, HER2/ECDwas significantly increased before
imaging conclusion ofmetastasis progression for bone, liver,
brain, and multiple organ metastases but not for lung
metastasis progression (Fig. 4A). Figure 4B and D revealed
non-significant decreases of HER2/ECD or CA 15.3 for each
specific metastasis localization. However, to considerer
therapeutic efficacy, we observed not only biomarker chan-
ges but also if the level remained elevated or below the ref-
erence value. Thus, each HER2/ECD evolution was
consistent with imaging conclusion in 94 %against 85 % for
CA 15.3 (Table 3). HER2/ECD predicted the metastasis
evolution in 100 % for liver and multiple organ metastases
(Table 3). A lower performance to predict bone, lung, and
brain metastasis progression or regression was observed (90,
89, and 90 % of correlation, respectively) (Table 3). It
appeared that CA 15.3 had lower percentages of correlation
(Table 3) but discrepancies in both HER2/ECD and CA 15.3
were never observed in a single event, suggesting once again
the complementarity of these biomarkers. In consequence,
HER2/ECD was useful to predict the fate of metastases.
Discussion
Our study aimed at analyzing a large cohort of patients
treated for an invasive breast cancer with overexpression of
HER2 status the usefulness of HER2/ECD measurements
Table 2 Correlation between HER2/ECD at diagnosis and age, N,








\45 56 (85 %) 10 (15 %) 0.0865
C45 to\55 103 (90 %) 11 (10 %)
C55 124 (81 %) 30 (19 %)
Lymph node status
N0 162 (86 %) 26 (14 %) 0.9449
N? (pTNM) 114 (85 %) 20 (15 %)
No dataa 7 5
Vascular invasion
VI- 239 (83 %) 49 (17 %) 0.0458
VI? 44 (96 %) 2 (4 %)
Metastatic status
M0 258 (90 %) 28 (10 %) <0.0001
M? 25 (52 %) 23 (48 %)
Grade
Low grade 15 (94 %) 1 (6 %) 0.5832
Intermediate grade 103 (84 %) 19 (16 %)
High grade 158 (84 %) 30 (16 %)
No dataa 7 1
Estrogen receptor status
ER- 95 (79 %) 25 (21 %) 0.0283
ER? 188 (88 %) 26 (12 %)
Progesterone receptor status
PR- 182 (84 %) 34 (16 %) 0.8691
PR? 101 (86 %) 17 (14 %)
Tissue HER2 status
HER2 2? ISH? 27 (90 %) 3 (10 %) 0.5946
HER2 3? 256 (84 %) 48 (16 %)
CA 15.3
\30 252 (91 %) 26 (9 %) <0.0001
C30 31 (55 %) 25 (45 %)
a Patients not operated or no Roche score on breast carcinoma
N lymph node, VI vascular invasion, M metastasis; ER estrogen
receptor, PR progesterone receptor
254 Breast Cancer Res Treat (2016) 160:249–259
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in the clinical management. The study was monocentric:
the inclusion of patients, surgery, follow-up, anato-
mopathology, and clinical chemistry were done in the same
departments during all the studies. Furthermore, we worked
with a validated and standardized assay for HER2/ECD
measurements as recommended by the FDA. Results
showed that HER2/ECD levels at diagnosis were more
elevated in advanced breast cancer that HER2/ECD is not a
substitute for HER2 status determination, that circulating
HER2/ECD levels at diagnosis are significantly correlated
with clinical outcome, and that HER2/ECD can be useful
in monitoring the efficacy of trastuzumab neoadjuvant
treatment and in assisting the early detection of relapse.
At diagnosis, we described a much higher prevalence of
elevated HER2/ECD levels in metastatic breast cancers
than in non-metastatic ones. In a review, Carney et al. also
found that the prevalence of elevated HER2/ECD levels
was more frequent in patients with metastatic breast cancer
than in women with primary breast cancer [21]. Therefore,
the presence of high HER2/ECD levels at diagnosis in
patients with HER2 overexpressing breast cancer may be a
sign of metastatic disease, and possible distant metastases
must be actively searched for. Consequently, early
screening for elevated HER2/ECD levels may increase the
sensitivity of detecting metastatic cancer.
Some authors have proposed to use serum HER2/ECD
concentration as an alternative to histological determina-
tion of tissue HER2 status [16, 22]. Our data did not sup-
port this idea, as among all tumors of this study with HER2
overexpression, only 15 % of them had an elevated HER2/
ECD value (C15 ng/mL). The lack of correlation between
HER2 and HER2/ECD can be explained by the fact that
elevated HER2/ECD levels may represent a subgroup of
HER2-positive tumors with a higher level of HER2
cleavage and shedding linked to a more aggressive clinical
course [23]. The shedding of HER2/ECD that is mediated
Fig. 2 Kaplan–Meier estimates for (A) disease-free, (B) progression-free, and (C) overall survival according to serum HER2/ECD levels at
diagnosis
Fig. 3 Kinetics of (A) HER2/ECD and (B) CA 15.3 during neoadju-
vant (NA) treatment in the complete (n = 7) and incomplete (n = 16)
histological response groups Biomarker levels were examined at three
time points during the NA treatment; first, before NA chemotherapy
beginning, then, before the addition of trastuzumab to the chemother-
apy, and finally, at the end of all NA treatments right before surgery
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by matrix metalloproteinases (MMPs) raises potential
explanations. Although cancer cells from various tissues
can express members of the MMP and ADAM (A Disin-
tegrin and metalloproteinase) families as well as their
inhibitors (TIMPs), the major source of these proteinases is
from the stroma cells infiltrating the tumor [24]. In our
study, elevated levels of HER2/ECD correlated positively
with parameters related to tumor aggressiveness, such as
vascular invasion, metastatic status, or negativity of
estrogen receptors, but not with invaded lymph nodes and
progesterone receptor-negative tumors. The literature has
frequently reported the correlation between high levels of
HER2/ECD and lymph node involvement [25–27]. In our
study, lymph nodes were considered as invaded even in
cases where there is only a micrometastasis, thus we did
not discriminate the invasion intensity and the number of
invaded lymph nodes. This probably explains the observed
lack of correlation.
We demonstrated that an elevated value of HER2/ECD
at diagnosis was strongly associated with a poor overall
survival in our cohort of women, and that it was an inde-
pendent prognostic factor. The link between the HER2/
ECD level and survival has several explanations. First, the
truncated HER2 form is 10 to 100-fold more oncogenic
than the full-length HER2 form [5]. Furthermore, the
binding of therapeutic anti-HER2 antibodies on HER2/
ECD neutralizes the biological activity of bound anti-
HER2 antibodies [28, 29]. Thus, the inhibition of HER2-
expressing tumor cells by therapeutic antibodies is limited
for patients with high amounts of HER2/ECD. This leads to
a more aggressive clinical course for this group of patients.
HER2/ECD appears to be a useful biomarker to identify
this subgroup of tumors and to improve the risk stratifi-
cation. This is of great importance as key decisions in the
current management of breast cancer involve the determi-
nation of prognosis.
This study shows preliminary results indicating that
HER2/ECD could also be intended for the monitoring of
trastuzumab neoadjuvant treatment efficacy. Patients with a
histological complete response showed a significant
decrease in the HER2/ECD level that was correlated with
the clinical course of disease. This effect was not observed
for patients with an incomplete histological response. Few
studies have evaluated the variations in levels during a
neoadjuvant treatment in patients with tumors overex-
pressing HER2. Two small prospective studies [30, 31]
Fig. 4 HER2/ECD and CA 15.3 changes during the 3 months before
medical imaging of metastasis breast cancer. Correlation of biomark-
ers with imaging results: HER2/ECD level changes during metastasis
(A) progression and (B) regression. CA 15.3 level changes during
metastasis (C) progression and (D) regression. No P data: due to
small sample size
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reported a reduction in HER2/ECD between the neoadju-
vant therapy conducted before and 1, 3, and 6 weeks after
beginning. This reduction was associated with a complete
histological response. Such an impact of trastuzumab
therapy on HER2/ECD is explained by the fact that the
trastuzumab binding site is near the cleavage site of HER2
[32]. The fixation of trastuzumab to its binding site inter-
feres with HER2 cleavage via steric hindrance of the
enzyme substrate interaction [33]. Consequently, trastu-
zumab induces HER2/ECD decrease by blocking HER2
cleavage. However, trastuzumab could be inefficient due to
the absence of trastuzumab fixation on HER2 after ele-
vated HER2/ECD cleavage. In such a situation, a constant
or an increasing HER2/ECD level could reveal that the
treatment is not effective, and HER2/ECD can be used as
an indicator for a second-line therapy based on lapatinib
which acts through a different mechanism from that of
trastuzumab. Lapatinib induces an inactivation of HER2
tyrosine kinase domain and maximizes trastuzumab-de-
pendent cell cytotoxicity [5]. Another resistance to tras-
tuzumab therapy could be due to the expression of a
truncated HER2 form that originally lacks ECD [34]. In
such a situation, HER2/ECD would have no interest, and
only the immunohistochemical determinations of both
HER2/ECD and HER2 intracellular domain (HER2/ICD)
could be of interest to observe this truncated form and
predict trastuzumab resistance [35].
HER2/ECD can also be appropriate to detect early
cancer recurrence as proposed by Carney et al. [33] and as
shown in this study, but not in all situations. We observed
an isolated increase of HER2/ECD in 18.6 % cases before
the diagnosis of relapse or metastasis, and an isolated
increase of CA 15.3 in 8.6 % cases before diagnosis of
cancer recurrence. Furthermore, HER2/ECD presented a
high level of reliability during the monitoring of metastatic
breast cancer to predict progression or regression of
metastases before medical imaging. This would allow
clinicians to make necessary adjustments to drug combi-
nation or even prompt them to follow-up patients more
frequently. HER2/ECD showed greater concordance than
CA 15.3 but the reliability increased when HER2/ECD is
concomitantly used with CA 15.3. This result was also
observed by Esteva et al. [36]. Consequently, these
markers are not interchangeable, but complementary.
Indeed, CA 15.3 measures circulating levels of fragments
of MUC1/Polymorphic Epithelial Mucin, present on all
breast cancer cells, whereas HER2/ECD is a part of HER2.
In this study, the 5 years overall survival was 97.5 % for
non-metastatic patients, better than the expected 90 % for
such a cohort with HER2 overexpression [37]. Taking into
account, the HER2/ECD level allowed an earlier diagnosis
of recurrences and consequently more treatment adjust-
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the early treatment by trastuzumab of a HER2 overex-
pressing non-symptomatic metastasis could increase
patient survival, we support the idea that these results stem
from using HER2/ECD during the follow-up.
Conclusion
Our study brings evidences to support the use of HER2/
ECD in the routine management of HER2-positive breast
cancer patients. At diagnosis, HER2/ECD measurement
can be useful to obtain a reference value before treatment,
and can be used as a prognosis factor. During the moni-
toring of neoadjuvant treatment, the evolution of HER2/
ECD levels is an informative element to evaluate the
therapeutic efficiency. In no case can it be the solely
indicator of the treatment efficiency. After clinical remis-
sion, HER2/ECD determination is an additional surveil-
lance biomarker helpful for the early diagnosis of relapses.
In all cases, the score of a circulating marker measurement
should always be interpreted according to the clinical
context and the results of other explorations.
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